RECOMBINATE 1000 IU

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL

MAH:

TEVA MEDICAL MARKETING LTD.

ATC_code:

B02BD02

pharmaceutical_form:

POWDER FOR SOLUTION FOR INJECTION

administration_route:

I.V

manufactured_by:

BAXTER S.A., BELGIUM

therapeutic_group:

COAGULATION FACTOR VIII

therapeutic_indication:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

authorization_date:

2010-07-01